Literature DB >> 19969084

Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.

Ana Laura De Lella Ezcurra1, Mariela Chertoff, Carina Ferrari, Mariana Graciarena, Fernando Pitossi.   

Abstract

Inflammation, and in particular microglia activation, is regarded as a constant component of brain pathology in Parkinson's disease (PD). Microglial activation has been found in the substantia nigra (SN), one of the main brain regions affected in PD, for many years after the initiation of the disease. Although many studies point towards a deleterious role of inflammation on PD, the functional role of many of its main components has not been clarified yet. For example, tumor necrosis factor-alpha (TNF-alpha), a key pro-inflammatory cytokine, has been shown to exert toxic or no effects on the viability of dopaminergic neurons. No study has evaluated the effects of the long-lasting TNF-alpha expression in the SN, an experimental set-up most probably resembling the clinical situation. The aim of this study was to investigate the effects of the chronic expression of TNF-alpha in the adult SN at different time points. Adenoviral expression of low TNF-alpha levels (17-19 pg/mg) lasted for 14 days in the SN and did not induce interleukin-1beta (IL-1beta) expression. Long-lasting TNF-alpha expression caused dopaminergic cell death from day 14, increasing at 21 and 28 days compared with control animals injected with adenovectors expressing beta-galactosidase. TNF-alpha overexpression elicited irreversible, unilateral akinesia starting at 14 days, but not earlier. These effects were accompanied by microglial activation to stage 4 and/or monocyte/macrophage recruitment from the periphery from day 7 post adenovector inoculations. Thus, we conclude that extended duration of the expression of TNF-alpha is necessary and sufficient for a univocal toxic effect of TNF-alpha on dopaminergic neurons and motor disabilities. This study provides an animal model to study early events that lead to TNF-alpha-mediated neuronal demise in the SN. In addition, the cellular components of the inflammation elicited by TNF-alpha and the lack of IL-1beta expression support the growing idea of a distinct cytokine network in the brain. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969084     DOI: 10.1016/j.nbd.2009.11.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  47 in total

1.  Head injury at early ages is associated with risk of Parkinson's disease.

Authors:  Kathryn M Taylor; Marie-Helene Saint-Hilaire; Lewis Sudarsky; David K Simon; Bonnie Hersh; David Sparrow; Howard Hu; Marc G Weisskopf
Journal:  Parkinsonism Relat Disord       Date:  2015-12-19       Impact factor: 4.891

Review 2.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 3.  Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Authors:  Sara L Montgomery; William J Bowers
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

4.  Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.

Authors:  Rosa Calvello; Antonia Cianciulli; Giuseppe Nicolardi; Francesco De Nuccio; Laura Giannotti; Rosaria Salvatore; Chiara Porro; Teresa Trotta; Maria Antonietta Panaro; Dario Domenico Lofrumento
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-16       Impact factor: 4.147

Review 5.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

Review 6.  Activated immune cells in Parkinson's disease.

Authors:  Jun-Jun Cao; Kang-Sheng Li; Yan-Qin Shen
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-10       Impact factor: 4.147

7.  Microglial activation and chronic neurodegeneration.

Authors:  Melinda E Lull; Michelle L Block
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 8.  Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.

Authors:  Chaitanya R Joshi; Vinod Labhasetwar; Anuja Ghorpade
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-03       Impact factor: 4.147

9.  4-Hydroxy TEMPO attenuates dichlorvos induced microglial activation and apoptosis.

Authors:  Aditya Sunkaria; Deep Raj Sharma; Willayat Yousuf Wani; Kiran Dip Gill
Journal:  ACS Chem Neurosci       Date:  2014-01-06       Impact factor: 4.418

10.  EP2 receptor signaling pathways regulate classical activation of microglia.

Authors:  Yi Quan; Jianxiong Jiang; Ray Dingledine
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.